Sirolimus before and after: what actually changes, and when

Last updated 2026-07-30

What does "sirolimus before and after" actually refer to?

People search this phrase expecting transformation photos, like a skincare ad. The honest answer is more complicated. There are three separate "before and after" stories tangled together under one search term, and conflating them is where most of the confusion on forums and social media comes from. The first is the transplant story: decades of before-and-after data on organ rejection rates, since sirolimus (brand name Rapamune) was FDA-approved in 1999 specifically to prevent rejection in kidney transplant patients ^[1]. The second is the topical story: sirolimus (as Hyftor, approved 2022) and older compounded topical formulations show measurable before-and-after skin changes in facial angiofibromas from tuberous sclerosis complex ^[2]. The third, and the one driving most search traffic, is the longevity story: people taking low-dose oral sirolimus off-label, hoping to replicate what happened in mice, and reporting their own before-and-after experience on blood panels, skin, joints, and energy. Only the first two have real human trial data behind the "after." The third is anecdote layered on top of strong animal science. That gap matters, and it's the subject of this whole article. Worth knowing up front: sirolimus and rapamycin are the same molecule. Rapamycin is the generic compound name (originally isolated from soil bacteria on Rapa Nui, Easter Island); sirolimus is the USAN/INN drug name used on prescriptions and labels. If you see both terms used interchangeably in a study or a forum post, that's not an error, it's just naming convention.

What happened in mouse studies, and how big were the effects?

This is the strongest part of the sirolimus story, and it deserves to be stated plainly with numbers instead of vague enthusiasm. The National Institute on Aging's Interventions Testing Program (ITP) has tested rapamycin across three independent lab sites (Jackson Laboratory, University of Michigan, University of Texas Health Science Center at San Antonio) using genetically heterogeneous mice, which is a much stronger design than a single-lab, single-strain study. In the original 2009 Nature paper, rapamycin started at 600 ppm in food at 20 months of age (roughly equivalent to a 60-year-old human starting treatment) extended median lifespan by 9% in males and 14% in females ^[3]. That's the study that made rapamycin famous in longevity circles, and it was notable specifically because the drug worked even when started late in life, unlike most interventions that only work if started young. Follow-up ITP work pushed further. Higher doses (42 ppm encapsulated, or higher ppm in food) and earlier starting ages produced larger effects, with some cohorts showing median lifespan increases in the 23-26% range for females at higher doses, and combination studies (rapamycin plus other compounds) occasionally exceeding that ^[4]. A widely cited figure of "up to 60% lifespan extension" comes from specific dose-and-sex combinations in later ITP reports, not a single uniform effect across all mice, so treat any single-number headline with some suspicion until you check which cohort and dose it refers to. The consistent findings across the ITP dataset: rapamycin is the only compound tested that reliably extends lifespan in both sexes across multiple independent cohorts, effects scale with dose up to a point, and starting later in life still produces a benefit, which is unusual and part of why researchers stayed interested ^[4].

Is there a completed human lifespan trial for sirolimus?

No. As of 2025, there is no completed randomized controlled trial that has measured whether rapamycin or sirolimus extends human lifespan. This is the single most important fact in the entire sirolimus longevity conversation, and it's worth restating anywhere the mouse data gets mentioned. What exists instead is a small set of human studies on surrogate markers, not lifespan itself. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), run through AgelessRx and published in 2024, was a randomized, placebo-controlled trial in adults over 50 using low doses (5mg or 10mg weekly) for 48 weeks. It found rapamycin was generally well tolerated and associated with improvements in some quality-of-life measures, but it was not designed or powered to measure lifespan or disease incidence, and the primary outcomes were safety and self-reported measures ^[5]. A separate widely cited small study looked at low-dose mTOR inhibition's effect on immune function in elderly volunteers, finding improved response to influenza vaccination, a proxy for immune aging, not a mortality outcome ^[6]. That's genuinely interesting mechanistic evidence but it is not the same as "people who took rapamycin lived longer." No trial has followed a cohort of healthy adults on low-dose rapamycin for the 10+ years it would take to see a mortality difference. Funding, cost, and the sheer duration required are the practical reasons this hasn't been done. Until it is, every human "before and after" claim about lifespan is extrapolation from mouse biology plus short-term biomarker changes, not a demonstrated human outcome.

What do people on off-label protocols actually report, and on what timeline?

Self-reported changes from people using intermittent low-dose sirolimus (commonly 3mg to 8mg once weekly, sometimes with brief on/off cycling) tend to cluster into a few categories. The timeline is fairly consistent across accounts even though the actual physiological cause of most of these reports isn't proven. Within 1 to 4 weeks: some users report mouth sores or a metallic taste, which is the most commonly reported early side effect and is well documented in the transplant literature as stomatitis, occurring in a meaningful minority of patients on standard immunosuppressive doses ^[1]. Within 4 to 12 weeks: reports of changes in skin texture, fewer minor infections in some, more minor infections in others, and shifts in fasting glucose or lipid panels on routine bloodwork. Within 3 to 6 months: some long-term users report improved joint comfort or skin appearance, which overlaps with sirolimus's approved topical use for skin lesions ^[2], but these are subjective and unblinded reports, not trial data. A table is more honest than a testimonial here: | Timeframe | Commonly reported change | Evidence quality |

What are the real risks behind the before-and-after story?

Sirolimus is a real immunosuppressant drug, approved at doses far higher than the longevity community uses, and its side effect profile at those approved doses is well characterized because it's been used in transplant medicine since 1999 ^[1]. The off-label, low-dose, intermittent protocols popular in longevity circles have not been studied at the same scale, so a lot of the risk profile is extrapolated downward from transplant data, which is a reasonable but imperfect approach. Mouth ulcers (stomatitis) are the single most common complaint, reported in a substantial share of transplant patients on standard dosing and frequently reported anecdotally even at low weekly doses ^[1]. Immunosuppression is the mechanistic core of the drug: it's an mTOR inhibitor, and mTOR inhibition dampens immune cell proliferation, which is exactly why it prevents transplant rejection and exactly why it may blunt vaccine response or slow recovery from infections in otherwise healthy people taking it off-label ^{[1] [6]}. Metabolic effects are also real and dose-related: rapamycin can raise LDL cholesterol and triglycerides and has been associated with new-onset insulin resistance in some transplant patients, an effect that's paradoxical given the mouse longevity data and is an active area of research into whether intermittent dosing avoids it ^[1]. Other known risks from the prescribing label include impaired wound healing, increased infection risk, and rare but serious lung inflammation (interstitial lung disease) at higher sustained doses ^[1]. None of this means low-dose intermittent use is unsafe for everyone, but it does mean "before and after" photos or testimonials that only show the upside are giving you half the picture. Anyone considering this should be doing it with bloodwork (lipid panel, fasting glucose, CBC) and physician oversight, not self-directed dosing from an online source with no clinical follow-up. See sirolimus pros and cons for a fuller risk-benefit breakdown.

How is sirolimus actually approved to be used, versus how longevity users use it?

The FDA-approved uses for sirolimus are narrow and specific, and none of them is anti-aging. Rapamune (oral sirolimus) is approved for prophylaxis of organ rejection in kidney transplant patients aged 13 and older ^[1]. Fyarro (albumin-bound sirolimus, nab-sirolimus) is approved for a rare cancer called malignant perivascular epithelioid cell tumor (PEComa) ^[7]. Hyftor (topical sirolimus 2% gel) is approved for facial angiofibromas associated with tuberous sclerosis complex in patients 6 and older ^[2]. Longevity users take oral generic sirolimus, prescribed off-label, usually at doses roughly a tenth to a third of standard transplant maintenance doses, and usually once weekly instead of daily. This intermittent dosing strategy is based on the theory, supported by some mouse pharmacokinetic work, that pulsed high-trough exposure hits mTORC1 (the target associated with lifespan benefits) while sparing mTORC2 (the target associated with the metabolic side effects), though this mechanistic separation is cleaner in theory than it's been proven in humans ^{[4] [1]}. That's an entirely legal thing for a physician to prescribe (off-label prescribing is legal and common in U.S. medicine), but it means the person taking it is relying on their prescriber's judgment and the mouse literature, not on a package insert that covers this use case.

How does sirolimus compare to other longevity-adjacent drugs people ask about?

Metformin is the most common comparison, since it's cheap, well tolerated, and has decades of safety data from diabetes use, but its human longevity evidence is arguably weaker than rapamycin's mouse evidence: metformin did not extend lifespan in the same NIA ITP mouse testing program at the doses tested, and the ongoing TAME trial (Targeting Aging with Metformin) has not yet reported results. Acarbose, another ITP-tested compound, showed lifespan extension in male mice (up to around 20% in some cohorts) but weaker or absent effects in females ^[4]. Rapamycin stands out in the ITP dataset specifically because it works in both sexes, across multiple labs, and even when started late in life, which is a more demanding bar than most compounds clear ^{[3] [4]}. That's the real basis for the longevity community's interest, not marketing. None of these compounds, including rapamycin, has a completed human trial proving lifespan extension. The honest comparison is: rapamycin has the strongest animal case, metformin has the most human safety history, and nobody has the human longevity data yet for either one. If you want the fuller comparison table, sirolimus success rate breaks down effect sizes by study.

What do actual before-and-after case reports and small studies show?

Beyond the mouse ITP data and the PEARL trial, a handful of smaller human studies give partial before-and-after snapshots, each narrow in scope. The topical sirolimus trials for facial angiofibromas (which led to Hyftor's approval) showed measurable reduction in lesion size and redness over 12 weeks of twice-daily application in the trials submitted to FDA ^[2]. That's a genuine, photographable, FDA-recognized before-and-after, but it's about a specific skin condition in tuberous sclerosis patients, not general anti-aging skin improvement. The elderly vaccine-response study mentioned earlier found that low-dose RAD001 (everolimus, a rapamycin analog) improved antibody response to influenza vaccination compared to placebo in adults over 65, suggesting a partial reversal of age-related immune decline ^[6]. That's a before-and-after on an immune biomarker, not a symptom or a lifespan outcome, and it used a rapamycin analog rather than sirolimus itself. The PEARL trial's published results describe improvements in certain patient-reported outcome measures over 48 weeks at 5mg and 10mg weekly doses, alongside a safety profile the authors described as consistent with known sirolimus effects, without serious adverse events attributable to the drug in that cohort ^[5]. Read the study yourself rather than taking secondhand summaries at face value. What's missing from all of this: no study has tracked all-cause mortality, cardiovascular events, cancer incidence, or dementia onset in a large human cohort on low-dose rapamycin over years. That's the actual "after" that would settle the debate, and it doesn't exist yet.

Who is a reasonable candidate to try low-dose sirolimus off-label, and who should not?

This isn't a question with a universal answer, and anyone claiming certainty here is overselling. But some patterns are worth stating plainly based on the known pharmacology. People who are immunocompromised already, have active infections, are pregnant or breastfeeding, have poorly controlled diabetes or significant dyslipidemia, or have a history of interstitial lung disease are generally poor candidates given sirolimus's known mechanism and side effect profile ^{[1] [1]}. People considering elective surgery should stop well in advance given documented wound-healing impairment ^[1]. For everyone else considering it, the reasonable version of this looks like: bloodwork before starting (lipid panel, fasting glucose/HbA1c, CBC, kidney function), a prescribing physician who understands mTOR pharmacology and will actually order follow-up labs, a conservative starting dose, and realistic expectations that the mouse lifespan data doesn't automatically transfer to a human on a weekly pill. That's the provider-reviewed route Sirolimus Rx is built around, connecting patients with prescribers who order labs and monitor for the known risks, with prescriptions filled through a licensed pharmacy partner rather than an unregulated online seller. For a plainer bottom-line judgment call, see is sirolimus worth it.

What should you track if you want a real before-and-after picture?

If you're going to do this, do it like a small experiment on yourself, not a vibe check. The people who get useful signal out of low-dose sirolimus are the ones who baseline their numbers before starting and recheck on a schedule, not the ones who just wait to feel different. Minimum reasonable panel before starting: fasting glucose and HbA1c, full lipid panel, complete blood count, kidney function (creatinine/eGFR), and liver function tests. Recheck at 8-12 weeks and again at 6 months, since lipid and glucose shifts are the most consistently documented metabolic effect in the literature ^[1] and are the thing you can actually catch early with bloodwork rather than guessing from how you feel. Track subjective measures too, but hold them loosely: skin appearance, joint comfort, sleep, recovery from minor illness, mouth sensitivity. Write them down at baseline. Most people badly misremember how they felt three months ago without a written baseline, which is exactly why testimonial-based "before and after" claims are so unreliable in both directions, people both overclaim benefit and underreport side effects when relying on memory alone. For a broader read on what other users have reported across these categories, sirolimus reviews collects patterns across a larger set of accounts.

Frequently asked questions

Does sirolimus actually reverse aging in humans?

No human trial has shown sirolimus reverses aging or extends lifespan. The strong reversal-type data (skin lesion shrinkage, improved vaccine response) comes from narrow conditions or short biomarker studies, not a demonstrated anti-aging effect across the body. The mouse lifespan extension data is real and substantial, but it hasn't been replicated as a lifespan outcome in humans ^[3][4][5].

How long before you see results on sirolimus?

Side effects like mouth ulcers can appear within days to a few weeks. Lab changes (lipids, glucose) often show up by 8-12 weeks. Subjective changes people report (skin, energy, joints) are usually described in the 3-6 month range, but these are self-reported and not verified by controlled trials in the longevity context ^[7][8].

Is sirolimus the same as rapamycin?

Yes. Rapamycin is the compound's original name; sirolimus is the official drug name (USAN/INN) used on prescriptions in the U.S. They're the same molecule and the terms are used interchangeably in medical literature and casual conversation alike.

What is the NIA Interventions Testing Program and why does it matter for sirolimus?

It's a National Institute on Aging program testing longevity compounds across three independent labs using genetically diverse mice, which is a stronger design than single-lab studies. Rapamycin is the program's standout result, extending median lifespan by 9-14% at standard doses starting at 20 months of age, with larger effects at higher doses in some cohorts ^[3][4].

Has anyone done a human lifespan trial on rapamycin?

No. As of 2025, no completed randomized trial has measured whether rapamycin extends human lifespan. Existing human studies (like PEARL) look at safety, quality-of-life measures, or biomarkers over months, not mortality over years or decades ^[5].

What are the most common side effects people report with low-dose sirolimus?

Mouth ulcers (stomatitis) are the most frequently reported, especially early on. Other documented effects include elevated LDL cholesterol and triglycerides, immune suppression, slower wound healing, and in rare cases at higher doses, lung inflammation ^[1][7][8].

Can sirolimus suppress your immune system at low longevity doses?

Yes, it's an mTOR inhibitor by design, and mTOR inhibition affects immune cell proliferation, which is exactly why it's used to prevent transplant rejection. At low intermittent doses, the suppression is presumed milder, but a study on the analog RAD001 showed measurable effects on vaccine antibody response even at low doses ^[6].

Is sirolimus FDA-approved for anti-aging?

No. Sirolimus is FDA-approved for kidney transplant rejection prophylaxis (Rapamune), a rare cancer called PEComa (Fyarro), and facial angiofibromas in tuberous sclerosis (Hyftor). Any use for aging or longevity is entirely off-label ^[1][2][9].

What dose do longevity users typically take, and is that studied?

Common off-label protocols use 3-10mg once weekly, far below standard transplant maintenance doses. The PEARL trial tested 5mg and 10mg weekly doses over 48 weeks and found them generally well tolerated, but this trial measured safety and quality-of-life outcomes, not lifespan or disease prevention ^[5].

Does sirolimus affect cholesterol and blood sugar?

Yes. Elevated LDL cholesterol and triglycerides are a documented effect of sirolimus, and it has been associated with new-onset insulin resistance in some transplant patients. This is why baseline and follow-up bloodwork (lipid panel, glucose/HbA1c) matters for anyone using it off-label ^[8].

How does sirolimus compare to metformin for longevity?

Rapamycin has stronger animal evidence: it extends lifespan in both sexes across multiple ITP mouse cohorts, even when started late in life. Metformin did not show the same lifespan extension in ITP mouse testing, though it has a longer human safety record from diabetes treatment. Neither has a completed human longevity trial ^[4][10].

Where can you get sirolimus prescribed for off-label longevity use?

It requires a prescribing physician willing to prescribe off-label, ideally one who orders baseline and follow-up labs. Provider-reviewed platforms like Sirolimus Rx connect patients with prescribers and route prescriptions through a licensed pharmacy partner, rather than unregulated online sellers with no clinical oversight.

Sources

1. FDA, Rapamune (sirolimus) prescribing information: Sirolimus (Rapamune) is FDA-approved for prophylaxis of organ rejection in kidney transplant patients, with known risks including impaired wound healing, infection risk, and interstitial lung disease
2. FDA, Hyftor (sirolimus topical gel) approval: Topical sirolimus 2% gel (Hyftor) is FDA-approved for facial angiofibromas in tuberous sclerosis complex patients 6 and older
3. Harrison DE et al., Nature (2009): Rapamycin extended median lifespan by 9% in males and 14% in females when started at 20 months of age in genetically heterogeneous mice
4. NIA Interventions Testing Program, published results summary: The NIA Interventions Testing Program has tested rapamycin and other compounds across three independent labs, with rapamycin showing lifespan extension in both sexes and at higher doses in later cohorts
5. Kaeberlein M et al., PEARL trial, GeroScience / Aging journal: The PEARL trial tested 5mg and 10mg weekly sirolimus doses in adults over 50 for 48 weeks, measuring safety and quality-of-life outcomes
6. Mannick JB et al., Science Translational Medicine (2014): Low-dose mTOR inhibition (RAD001/everolimus) improved influenza vaccine antibody response in elderly adults compared to placebo
7. FDA, Fyarro (nab-sirolimus) approval announcement: Fyarro (albumin-bound sirolimus) is FDA-approved for malignant PEComa, a rare soft tissue cancer